Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

X
Trial Profile

A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANX 005 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Annexon
  • Most Recent Events

    • 27 Apr 2023 Final results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 03 Nov 2022 According to an Annexon media release, data from this study will be presented at Huntingtons Study Group (HSG) 2022 Annual Meeting
    • 18 Sep 2022 Results assessing the safety, pharmacokinetics/pharmacodynamics, biomarkers, and efficacy of ANX005 in patients with huntingtons disease, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top